(Q36666922)

15 August 2017

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism (English)

1 reference

secondary hyperparathyroidism

15 August 2017

1 reference

1 reference

1

Piergiorgio Messa

1 reference

15 August 2017

Fernando Macário

2

1 reference

15 August 2017

Magdi Yaqoob

3

1 reference

15 August 2017

Koen Bouman

4

1 reference

15 August 2017

Johann Braun

5

1 reference

15 August 2017

Beat von Albertini

6

1 reference

15 August 2017

Hans Brink

7

1 reference

15 August 2017

Francisco Maduell

8

1 reference

15 August 2017

Helmut Graf

9

1 reference

15 August 2017

João M Frazão

10

1 reference

15 August 2017

Willem Jan Bos

11

1 reference

15 August 2017

Vicente Torregrosa

12

1 reference

15 August 2017

Heikki Saha

13

1 reference

15 August 2017

Helmut Reichel

14

1 reference

15 August 2017

Martin Wilkie

15

1 reference

15 August 2017

Valter J Zani

16

1 reference

15 August 2017

Bart Molemans

17

1 reference

15 August 2017

Dave Carter

18

1 reference

15 August 2017

Francesco Locatelli

19

1 reference

15 August 2017

language of work or name

1 reference

1 January 2008

1 reference

Clinical Journal of the American Society of Nephrology

15 August 2017

1 reference

15 August 2017

3

1 reference

15 August 2017

1

1 reference

15 August 2017

36-45

1 reference

Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Vitamin D analogues for the management of secondary hyperparathyroidism.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Pathogenesis of secondary hyperparathyroidism

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Analysis of renal bone disease treatment in dialysis patients.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Inter-method variability in PTH measurement: implication for the care of CKD patients.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Modulation and action of the calcium-sensing receptor.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Recent developments in the management of secondary hyperparathyroidism

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Valuation of EuroQOL (EQ-5D) Health States in an Adult US Sample

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

4 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2390975

Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

4 December 2018

1 reference

12 December 2020

Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)

1 reference

12 December 2020

Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy

1 reference

12 December 2020

The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure

1 reference

12 December 2020

Hyperparathyroidism in the hemodialysis population: a survey of 612 patients

1 reference

12 December 2020

A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism

1 reference

12 December 2020

Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.03591006

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

18178780

1 reference